Skip to content

Quick ratio at other companies

HRO
HarrowHROW
2.3×+1.4×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
4.9×+2.3×
XER
Xeris Biopharma Holdings, Inc.XERS
1.5×+0.3×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
1.9×-0.4×
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
2.5×+0.5×
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
18.6×-4.0×

Other financials

Income statement

See full
Revenue$24.3M+40.4%
Gross profit$14.7M+49.4%
Operating income$2.4M+614%
Net income$1.6M+199%
EPS (diluted)$0.05+183%

Balance sheet

See full
Cash & equivalents$19.7M+12.9%
Total debt$31.3M+3.7%
Total equity$30.6M+25.2%
Total assets$97.7M+16.3%

Cash flow

See full
Operating cash flow$7.4M+254%
CapEx$75.0K
Free cash flow$7.3M+251%

Valuation

See full
Market cap$930.79M+156%
Enterprise value$942.39M+150%
P/S10.7×+3.2×

Profitability

See full
Gross margin54.8%-3.7pp
Operating margin-15.1%
Net margin-9.5%-2.7pp
FCF margin17.1%

Returns & leverage

See full
Return on equity-34.2%+0.9pp
Debt / equity-0.2×
Current ratio1.2×-0.8×

Where this comes from

Calculated from Eton Pharmaceuticals, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eton Pharmaceuticals, Inc.'s quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Eton Pharmaceuticals, Inc.'s quick ratio?
Eton Pharmaceuticals, Inc. (ETON) reported quick ratio of 0.9× in Q1 2026.
How has Eton Pharmaceuticals, Inc.'s quick ratio changed year-over-year?
Eton Pharmaceuticals, Inc.'s quick ratio decreased by 38.8% year-over-year, from 1.4× to 0.9×.
What is the long-term trend for Eton Pharmaceuticals, Inc.'s quick ratio?
Over 5 years (2020 to 2025), Eton Pharmaceuticals, Inc.'s quick ratio has grown at a -28.3% compound annual growth rate (CAGR), from 6.2× to 1.2×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.